Verified Nov 2026
Other
·

San Diego, California
·
Since 2020
Travere Therapeutics is a San Diego-based biopharmaceutical company founded in 2008 and rebranded in 2020, with 500-1,000 employees and estimated revenue of $250-500 million. The company develops and commercializes therapies for rare kidney and metabolic diseases. Its approved therapies include Filspari for primary IgA Nephropathy and Thiola for cystinuria, while investigational candidates target conditions including Focal Segmental Glomerulosclerosis.
Travere Therapeutics at a glance
Revenue
$250-500M
Est. band
Employees
500-1,000
Founded
2020
Headquarters
San Diego, California
Industries
Automotive
Electric Vehicles
Medical
Overview
Travere Therapeutics is a San Diego-based biopharmaceutical company founded in 2008 and rebranded in 2020, with 500-1,000 employees and estimated revenue of $250-500 million. The company develops and commercializes therapies for rare kidney and metabolic diseases. Its approved therapies include Filspari for primary IgA Nephropathy and Thiola for cystinuria, while investigational candidates target conditions including Focal Segmental Glomerulosclerosis.
At a glance
Attribute | Detail |
|---|---|
Founded | 2020 |
Headquarters | San Diego, California |
Employees | 500-1,000 |
Revenue | $250-500M (estimated) |
What Travere Therapeutics makes
The company operates a therapeutic pipeline encompassing both approved and investigational treatments addressing rare kidney disease, cystinuria, and metabolic disease conditions.
Latest developments
2026-11-02 — Travere Therapeutics - Travere Therapeutics Reports Third Quarter 2026 Financial Results (travere.com)
2026-09-21 — Travere Therapeutics - Travere Therapeutics Announces Planned Chief Executive Officer Transition (travere.com)
2026-07-07 — Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib (everestmedicines.com)
2026-06-02 — Travere Therapeutics - Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases (travere.com)
2026-06-02 — Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion | Reuters (reuters.com)
2026-05-04 — Travere Therapeutics - Travere Therapeutics Reports First Quarter 2026 Financial Results (travere.com)
Facilities
Travere Therapeutics is headquartered in San Diego, California. Public sources also reference these locations:
San Diego, California — sec.gov
Company details
Travere maintains operations in the United States and Ireland, serving rare disease communities through direct engagement and patient-centered care programs. Travere Therapeutics was founded in 2020, has an estimated 500-1,000 employees, and is headquartered in San Diego, California.
Frequently asked questions
What does Travere Therapeutics do?
Travere Therapeutics is a San Diego-based biopharmaceutical company founded in 2008 and rebranded in 2020, with 500-1,000 employees and estimated revenue of $250-500 million. The company develops and commercializes therapies for rare kidney and metabolic diseases. Its approved therapies include Filspari for primary IgA Nephropathy and Thiola for cystinuria, while investigational candidates target conditions including Focal Segmental Glomerulosclerosis.
Where is Travere Therapeutics headquartered?
Travere Therapeutics is headquartered in San Diego, California (3611 Valley Centre Dr, San Diego, California, 92130-3324).
When was Travere Therapeutics founded?
Travere Therapeutics was founded in 2020.
How big is Travere Therapeutics?
Travere Therapeutics has an estimated 500-1,000 employees, with revenue in the $250-500M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
